Recent Posts
- Sermonix to Host Virtual Clinical Update on its ELAINE Phase 2 Clinical Programs
- Sermonix Pharmaceuticals’ Phase 2 Lasofoxifene Trial Poster Receives a GRASP Advocate Choice Award, Selected for Post-ASCO Patient Advocate Investigator Discussions
- Sermonix to Present Updated Data from ELAINE-2 Clinical Trial of Lasofoxifene in Combination with Abemaciclib in Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1 Mutation after Progression on Prior Therapies at the 2022 ASCO Annual Meeting
- Sermonix Announces Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
- Biotech raises $40M to test forgotten osteoporosis drug in treatment-resistant breast cancer
Recent Comments